GAMMA Investing LLC Grows Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

GAMMA Investing LLC raised its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRKFree Report) by 51.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 788 shares of the company’s stock after purchasing an additional 269 shares during the quarter. GAMMA Investing LLC’s holdings in Scholar Rock were worth $34,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock valued at $310,000 after purchasing an additional 379 shares in the last quarter. Exome Asset Management LLC purchased a new position in shares of Scholar Rock during the third quarter valued at $1,115,000. Barclays PLC raised its holdings in shares of Scholar Rock by 103.4% in the third quarter. Barclays PLC now owns 165,449 shares of the company’s stock valued at $1,324,000 after acquiring an additional 84,118 shares in the last quarter. Geode Capital Management LLC lifted its stake in Scholar Rock by 8.5% in the third quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company’s stock worth $12,361,000 after acquiring an additional 120,489 shares during the period. Finally, Wellington Management Group LLP lifted its stake in Scholar Rock by 16.2% in the third quarter. Wellington Management Group LLP now owns 199,777 shares of the company’s stock worth $1,600,000 after acquiring an additional 27,801 shares during the period. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Stock Down 2.5 %

Scholar Rock stock opened at $41.53 on Wednesday. The stock has a market cap of $3.89 billion, a PE ratio of -17.67 and a beta of 0.52. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The stock’s fifty day moving average is $38.15 and its two-hundred day moving average is $22.08. Scholar Rock Holding Co. has a 1-year low of $6.76 and a 1-year high of $46.19.

Analyst Upgrades and Downgrades

SRRK has been the topic of several recent research reports. HC Wainwright increased their target price on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Truist Financial raised their price objective on Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. JPMorgan Chase & Co. boosted their target price on shares of Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, October 14th. Wedbush restated an “outperform” rating and issued a $47.00 price target on shares of Scholar Rock in a report on Thursday, January 9th. Finally, Piper Sandler lifted their price objective on shares of Scholar Rock from $28.00 to $42.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $40.43.

Check Out Our Latest Analysis on Scholar Rock

Insider Buying and Selling at Scholar Rock

In related news, major shareholder Public Equities L.P. Invus sold 409,433 shares of Scholar Rock stock in a transaction on Monday, November 25th. The stock was sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the completion of the transaction, the insider now directly owns 10,850,005 shares of the company’s stock, valued at approximately $417,616,692.45. The trade was a 3.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 19.20% of the stock is owned by company insiders.

Scholar Rock Profile

(Free Report)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Further Reading

Institutional Ownership by Quarter for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.